Best of ASCO - 2014 Annual Meeting



Attend this session at the
2018 ASCO Annual Meeting!

Session: Genitourinary (Prostate) Cancer

Type: Oral Abstract Session

Time: Monday June 4, 3:00 PM to 6:00 PM

Location: Hall D1

Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).

Advanced Disease

Genitourinary (Prostate) Cancer

2018 ASCO Annual Meeting

Abstract No:

J Clin Oncol 36, 2018 (suppl; abstr LBA5005)

Author(s): Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel Peter Petrylak, Ian Murchie Thompson, Kim N. Chi, Johann S. De Bono, Abderrahim Fandi, John C. Araujo, Mario A. Eisenberger, Christopher Logothetis, David I. Quinn, Karim Fizazi, Celestia S. Higano, Daniel J. George, Michael J. Morris, Eric Jay Small, Ian Tannock, William Kevin Kelly; Duke University Medical Center, Durham, NC; Duke University, Durham, NC; Fred Hutchinson Cancer Research Center, Seattle, WA; The Royal Melbourne Hospital, Parkville, Australia; Yale School of Medicine, New Haven, CT; UT Health Science Center, San Antonio, TX; British Columbia Cancer Agency - Vancouver Centre, Vancouver, BC, Canada; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Celgene, Summit, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; University of Texas MD Anderson Cancer Center, Houston, TX; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Gustave Roussy, Villejuif, France; University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan Kettering Cancer Center, New York, NY; University of California San Francisco, San Francisco, CA; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

Abstract Disclosures


Background: Reports have suggested that African-American (AA) men with metastatic castration-resistant prostate cancer (mCRPC) have shorter overall survival (OS) than Caucasian (C) men. Prior reports have been limited by small sample size. The primary goal of this analysis was to compare OS in AA men to Caucasian men treated with docetaxel/prednisone or a docetaxel/prednisone containing regimen. Methods: Individual patient data from 8,871 mCRPC men randomized on nine phase III trials to docetaxel/prednisone (DP) or a DP containing regimen were combined. Race used in the analysis was based on self-report. The primary endpoint is OS, defined as the time between randomization and death or date of last follow-up if patients were alive. The proportional hazards model was used to assess the prognostic importance of race (AA vs. C) adjusting for established risk factors that were common across the trials (age, PSA, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). Results: Of 8,871 patients, 7,528 (85%) were C, 500 (6%) were AA, 424 were Asian (5%) and 419 (4%) had race unspecified. The last two groups were deleted from the analysis leaving 8,452 pts. Median age was 69 years and 94% had performance status 0-1. Median hemoglobin, PSA and alkaline phosphatase were 12.9 g/dL, 86 ng/mL and 139 U/L, respectively. Pattern of metastatic spread were: 72% bone disease with or without lymph nodes, 9% lung disease, 9% liver disease and 7% lymph nodes only. Median OS were 21.0 (95% CI = 19.4-22.5) vs. 21.2 months (95% CI = 20.8-21.7) in AAs and C, respectively. In multivariable analysis adjusting for established risk factors, the pooled hazard ratio (HR) for AAs vs. Caucasians was 0.81 (95% CI = 0.72-0.92, p-value = 0.001) in all patients. Similar results were observed in 4,172 of patients who were treated with DP. Conclusions: We observed a statistically significant increased OS in AA vs. C men with mCRPC who were eligible to be enrolled on these clinical trials. Further understanding the biological variation by race in men with mCRPC treated with DP is warranted.

Other Abstracts in this Sub-Category:


1. A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5000 First Author: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen
Category: Genitourinary (Prostate) Cancer - Advanced Disease


2. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5001 First Author: Wolfgang Fendler
Category: Genitourinary (Prostate) Cancer - Advanced Disease


3. Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5003 First Author: Noel Clarke
Category: Genitourinary (Prostate) Cancer - Advanced Disease